

disease; and skin diseases. The present invention also provides a method of preventing or treating type II diabetes using the anti-AM monoclonal antibody. AM peptides and antibodies can also be utilized for diagnosis and treatment of preeclampsia and to promote fetal growth.

The present invention provides a method of regulating activity in areas of the central nervous system by administering to a subject an effective amount of AM peptides or antibodies for the regulation of neurotransmission or neuron growth. i.e. Alzheimer's disease. Administering antibodies to AM can inhibit the degranulation of mast cells and provide a method of lessening or inhibiting the allergic response due to the degranulation of mast cells. AM peptides have also been found to inhibit bacterial or fungal growth and facilitate the healing of chaffed skin, skin lesions, wound repair, and surgical incisions. AM peptides promote organ and bone development. (portfolio: Cancer—Therapeutics; Central Nervous System—Therapeutics; Infectious Diseases—Therapeutics; Internal Medicine—Therapeutics)

Dated: July 17, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-19180 Filed 7-26-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings.

Purpose/Agenda: To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: August 9, 1996.

Time: 8:30 a.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435-1782.

Name of SEP: Clinical Sciences.

Date: August 9, 1996.

Time: 10:30 a.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435-1782.

Name of SEP: Clinical Sciences.

Date: August 9, 1996.

Time: 2:30 p.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435-1782.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Biological and Physiological Sciences.

Date: August 15, 1996.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 5126, Telephone Conference.

Contact Person: Dr. Anne Clark, Scientific Review Administrator, 6701 Rockledge Drive, Room 5126, Bethesda, Maryland 20892, (301) 435-1017.

Name of SEP: Behavioral and Neurosciences.

Date: August 16, 1996.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 5179, Telephone Conference.

Contact Person: Dr. Luigi Giacometti, Scientific Review Administrator, 6701 Rockledge Drive, Room 5179, Bethesda, Maryland 20892, (301) 435-1246.

Name of SEP: Biological and Physiological Sciences.

Date: August 19, 1996.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 5126, Telephone Conference.

Contact Person: Dr. Anne Clark, Scientific Review Administrator, 6701 Rockledge Drive, Room 5126, Bethesda, Maryland 20892, (301) 435-1017.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 20, 1996.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4178, Telephone Conference.

Contact Person: Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4178, Bethesda, Maryland 20892, (301) 435-1146.

Name of SEP: Clinical Sciences.

Date: August 28, 1996.

Time: 8:00 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 22, 1996.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 96-19179 Filed 7-26-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Commission Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: July 29, 1996.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 4192, (Telephone Conference).

Contact Person: Dr. Lynwood Jones, Scientific Review Administrator, 6701 Rockledge Drive, Room 4192, Bethesda, Maryland 20892, (301) 435-1153.

Name of SEP: Clinical Sciences.

Date: July 29-30, 1996.

Time: 2:00 p.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Shirley Hilden, Scientific Review Administrator, 6701 Rockledge Drive, Room 4218, Bethesda, Maryland 20892, (301) 435-1198.

Name of SEP: Chemistry and Related Sciences.

Date: August 1, 1996.

Time: 12:00 p.m.

Place: NIH, Rockledge 2, Room 5104, (Telephone Conference).

Contact Person: Dr. Donald Schneider, Scientific Review Administrator, 6701 Rockledge Drive, Room 5104, Bethesda, Maryland 20892, (301) 435-1165.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 24, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-19254 Filed 7-24-96; 4:52 pm]

BILLING CODE 4140-01-M